Cowen & Co. analyst Boris Peaker maintained a Buy rating on Surface Oncology (SURF) today. The company’s shares closed last Monday at $1.62, close to its 52-week low of $1.15.
According to TipRanks.com, Peaker is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -2.1% and a 39.3% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Pacira Pharmaceuticals, and Emergent Biosolutions.
Currently, the analyst consensus on Surface Oncology is a Moderate Buy with an average price target of $12.00, representing a 552.2% upside. In a report issued on November 12, JonesTrading also reiterated a Buy rating on the stock with a $12.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.94 and a one-year low of $1.15. Currently, Surface Oncology has an average volume of 55.25K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Surface Oncology, Inc. is a clinical-stage immuno-oncology company, which focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.
